SBL
MYOV

Sargent Bickham Lagudis’s Myovant Sciences Ltd. MYOV Stock Holding History

Sargent Bickham Lagudis’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-215
Closed -$6K – 811
2018
Q3 		$6K Hold
215
– – ﹤0.01% 679
2018
Q2 		$5K Buy
+215
New +$4.7K ﹤0.01% 673

Other funds holding MYOV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sargent Bickham Lagudis's MYOV Position: Q4 2018 in Review

Sargent Bickham Lagudis sold out of Myovant Sciences Ltd. (MYOV) in Q4 2018, closing a stake of 215 shares — an estimated $6K sold.

Sargent Bickham Lagudis first reported a position in MYOV in Q2 2018 and held it in 2 quarters. The position peaked at $6K in Q3 2018. 30 funds tracked by Wall St. Rank hold MYOV as of Q4 2018.

  • Sargent Bickham Lagudis reported no remaining Myovant Sciences Ltd. position as of Q4 2018 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 215 Myovant Sciences Ltd. shares in Q4 2018, an estimated $6K.
  • Sargent Bickham Lagudis first reported a position in Myovant Sciences Ltd. in Q2 2018 and held it in 2 quarters.
  • Sargent Bickham Lagudis's Myovant Sciences Ltd. position peaked at $6K in Q3 2018.
  • 30 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q4 2018.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2018, filed 13 Sep 2021.